Biogen files for MS drug approval; AstraZeneca touts PhIII data on opioid-induced constipation drug;

 @FierceBiotech: New special: Top 10 Biotech CEO Pay Packages of 2012 via @RyanMFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Bayer bolsters campaign for PAH drug riociguat with positive long-term data. More | Follow @JohnCFierce

 @RyanMFierce: Interviewed Regeneron's Yancopoulos, biotech's highest paid exec in 2012, about promising allergy drug and success recipe. Story | Follow @RyanMFierce

> Biogen Idec ($BIIB) has filed its BLA for Plegridy (peginterferon beta-1a) for multiple sclerosis. Release

> AstraZeneca ($AZN) had its coming out party for Phase III data on naloxegol at the Digestive Disease Week (DDW) meeting in Orlando. Investigators say they reaped positive data from a pair of Phase III studies for opioid-induced constipation. Naloxegol hit primary as well as all secondary endpoints in the studies. Release

> The U.K.'s ImmuPharma has raised £50 million to take its lead drug into late-stage testing. Story

> J&J's Janssen says that the Phase III PROMISE study demonstrated that simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment 79% of treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin. Release

Pharma News

 @FiercePharma: ICYMI: 20 Highest-Paid Biopharma CEOs of 2012. Feature Reactions? Use #FPexecpay. | Follow @FiercePharma

 @EricPFierce: Women sue Apotex over manufacturing issues that led to too many placebos and unexpected pregnancies. More | Follow @EricPFierce

> Warner Chilcott CEO up for $9.2M handshake after Actavis deal. News

> Novo A/S snatches up antibacterials-maker Xellia as part of new investment strategy. Article

> Will U.K. watchdogs change their minds on Avastin in ovarian cancer? More

Medical Device News

 @FierceMedDev: German cops seize Boston Scientific stents in cutthroat patent fight. More | Follow @FierceMedDev

 @MarkHFierce: It's that time of year again: We're seeking nominations for this year's fiercest medical device and Dx companies. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic rode some international sales success to quarterly revenue growth. Article | Follow @DamianFierce

> Medtronic, J&J's Cordis headline EuroPCR 2013. Article

> Interleukin Genetics raises $12M in last-ditch save. DxExtra

> Sequester cuts threaten FDA's access to industry user fees. Story

Biotech Research News

 @EmilyMFierce:  | Follow @EmilyMFierce

> Researchers pinpoint protein involved in cancer cell death. Item

> Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease. More

> Drug boosts effectiveness of radiation therapy for brain tumors. Story

> Scientists use cloning method to create embryonic stem cells. Article

Pharma Manufacturing News

> Novartis' Sandoz unit recalls products from U.S., Poland. News

> Chinese drugmaker fights counterfeiting in Africa with SMS technology. More

> Impax brings in big guns to get on top of manufacturing problems. Story

> Apotex sued over problems on contraceptive packaging line. Article

> Gorsky pleads with employees to think quality. More

And Finally… Officials at the WHO say that it's impossible to predict just how the outbreak of H7N9 will develop in the months to come. Story

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.